CATX – perspective therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Perspective Therapeutics (NASDAQ:CATX) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Perspective Therapeutics (NASDAQ:CATX) was given a new $16.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Form SCHEDULE 13G Perspective Therapeutics Filed by: MORGAN STANLEY
Form SCHEDULE 13G Perspective Therapeutics Filed by: Commodore Capital LP
Form SCHEDULE 13G Perspective Therapeutics Filed by: TCG Crossover GP II, LLC
Form SCHEDULE 13G Perspective Therapeutics Filed by: Qatar Investment Authority
Form 8-K Perspective Therapeutics For: Feb 02
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.